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Abstract
Background: Acute liver failure (ALF) is a clinical syndrome characterized by the sudden onset of
coagulopathy and encephalopathy. The outcome is unpredictable and is associated with high morbidity
and mortality. We reviewed our experience to identify the aetiology and study the outcome of acute liver
failure.
Methods: A total of 1237 patients who presented with acute liver failure between January 1992 and May
2008 were included in this retrospective study. Liver transplantation was undertaken based on the King's
College Hospital criteria. Data were obtained from the units prospectively collected database. The
following parameters were analysed: patient demographics, aetiology, operative intervention, overall
outcome, 30-day mortality and regrafts.
Results: There were 558 men and 679 women with a mean age of 37 years (range: 8–78 years). The most
common aetiology was drug-induced liver failure (68.1%), of which 90% was as a result of a paracetamol
overdose. Other causes include seronegative hepatitis (15%), hepatitis B (2.6%), hepatitis A (1.1%), acute
Budd–Chiari syndrome (1.5%), acute Wilson's disease (0.6%), subacute necrosis(3.2%) and miscella-
neous (7.8%). Three hundred and twenty-seven patients (26.4%) were listed for liver transplantation, of
which 263 patients successfully had the procedure (80.4%). The current overall survival after transplan-
tation was 70% with a median follow-up of 57 months. After transplantation for ALF, the 1-year, 5-year
and 10-year survival were 76.7%, 66% and 47.6%, respectively. The 30-day mortality was 13.7%. Out of
the 974 patients who were not transplanted, 693 patients are currently alive. Among the 281 patients who
died without transplantation, 260 died within 30 days of admission (26.7%). Regrafting was performed
in 31 patients (11.8%), the most common indication being hepatic artery thrombosis (11 patients).
Conclusion: Paracetamol overdose was the most common cause of acute liver failure. Liver trans-
plantation, when performed for acute liver failure, has good long-term survival.
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Introduction
Acute liver failure (ALF) is a clinical syndrome characterized
by the sudden onset of coagulopathy and encephalopathy in an
otherwise healthy person with no underlying liver disease. The
aetiology of ALF varies significantly worldwide. Paracetamol over-
dose is the predominant cause of ALF in the United Kingdom
(UK) and the United States (US).1,2 Viral aetiology is the most
common cause in the developing countries.3
ALF is associated with significant morbidity and mortality. The
outcome is highly unpredictable. The chance of recovery depends
on the underlying aetiology, age of the patient, duration of time
over which the disease develops, the extent of liver damage and
early institution of supportive care.3 Outcome without liver trans-
plantation is better overall in patients with pregnancy-related syn-
dromes, paracetamol overdose and hepatitis A, and poorer in
older patients and in very young children.4
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In recent years, liver transplantation has emerged as a viable
treatment option in patients with ALF. It is mainly employed
as a salvage therapy for individuals who are unable to recover
from ALF.
Although several studies are available in the literature regard-
ing the outcome of liver transplantation in ALF in the UK, only
limited data are available until date on the outcome of ALF
itself.5–8 Being one of the largest transplant centres in the UK, we
reviewed our experience to identify the aetiology and study the
outcome of patients with ALF.
Patients and methods
This is a retrospective descriptive study performed over a period
of 16 years, from January 1992 to May 2008. All patients who were
referred and admitted at the University Hospital of Birmingham
(UHB), with the diagnosis of ALF during the study period were
included. ALF was defined according to the criteria of O’Grady
et al., as the onset of hepatic encephalopathy occurring within 12
weeks of onset of jaundice.9 After admission to the liver intensive
care unit, the patients were managed with aggressive supportive
therapy and closely monitored under the joint care of liver
surgeons, hepatologists and intensivists. All patients with drug-
induced liver failure received N-acetyl cysteine whereas patients
with others causes of ALF did not. The criteria for listing for liver
transplantation were standardized and were based on the pre-
viously described King’s College Hospital criteria.10
Data were obtained from the prospectively maintained
liver database at the UHB. The parameters analysed were patient
demographics, aetiology of ALF, operative intervention, overall
outcome after transplantation, short-term outcome in non-
transplanted patients, post-transplant complications, re-grafts
and mortality.
Aetiological diagnosis was based on the detailed clinical infor-
mation and laboratory data. Viral aetiology was confirmed based
on the screening for serological markers of Hepatitis A, B, C and E
viral infections, including IgM antibodies against HAV and HBV
and for auto-antibodies. These include antinuclear antibodies,
antiliver-kidney microsome antibodies and anti-smooth muscle
antibodies. Drugs were implicated as aetiological agent based on
the detailed medical history at admission. Diagnosis of Wilson’s
disease was based on the serum copper and ceruloplasmin levels,
the presence of the Kayser–Fleisher ring and family history.
Diagnosis of Budd–Chiari syndrome was confirmed on abdomi-
nal imaging. Seronegative hepatitis is a presumed non-A,B,C,E
hepatitis with a hepatitic picture. Extensive medical history was
obtained from these patients to exclude intake of any dietary
or herbal supplements or medications that could cause ALF.
However, they did not have routine blood tests as a standard
protocol, to investigate for commonly implicated dietary supple-
ments (muscle building or weight loss medications or supple-
ments that include extracts of green tea). Subacute necrosis refers
to the time course of hepatitis, the jaundice to encephalopathy
time being greater than 8 weeks and less than 3 months.
Results are expressed as median and ranges. Data analysis
was done with SPSS for Windows® software (version 13; SPSS
Inc., Chicago, IL, USA). The overall survival was evaluated by
Kaplan–Meier analysis.
Results
During the study period, a total of 1237 patients were admitted
with the clinical diagnosis of ALF. There were 558 men and 679
women. The median age at presentation was 37 years (range: 8–78
years).
Aetiology of ALF
Drug-induced liver failure was the predominant causative
factor, accounting for 68.1% of patients admitted with ALF.
The most common drug implicated was paracetamol (90%). The
other drugs responsible for ALF are listed in Table 1. Twenty-four
patients, listed as ‘unknown drugs’, had a combination of multiple
drugs with alcohol as the only aetiological agent for ALF.
Table 1 List of drugs implicated in acute liver failure (ALF)
Drugs Number of patients
Paracetamol 759
Isoniazid 18
Ecstasy 8
Chinese herbal medicine 5
Halothane 2
Cocaine/alcohol 3
Voltarol 2
Augmentin 2
Carbamazepine 2
Rifampicin 1
Omeprazole 1
Clarithromycin 1
Chlordiazepoxide 1
Flucloxacillin 1
Fluoxetine 1
Dothiepen 1
Trimethoprim 1
Azathioprine 1
Phenytoin 1
Glivec 1
Sulphasalazine 2
Amiadarone 1
Chloroquine 1
Norethisterone 1
Orlestat 1
Antabuse 1
Unknown 24
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Fulminant seronegative hepatitis was deemed responsible in
15% of ALF. Hepatitis A and B viral infections accounted for
1.1% and 2.6%, respectively. The presumptive diagnoses of sub-
acute necrosis, acute Budd–Chiari syndrome and acute Wilson’s
disease were found to be responsible for ALF in 3.2%, 1.5% and
0.6%, respectively. Miscellaneous causes included pregnancy-
associated ALF, acute fatty liver, Epstein-Barr and hepatitis E viral
infections. This group accounted for ALF in 7.8% of patients.
Listing and transplantation
Three hundred and twenty-seven patients were listed for
emergency liver transplantation, of which 263 patients success-
fully received a liver graft (80.4% of listed patients and 21.3% of
all patients with ALF). The number of patients listed for emer-
gency orthotopic liver transplantation varied widely between dif-
ferent aetiological agents. Patients with acute Wilson’s disease or
fulminant seronegative hepatitis are likely to be listed for trans-
plantation, whereas hepatitis A viral infection and drug-induced
liver failure are less likely to be listed (Table 2). Transplantation
was performed in only 10.4% of the drug-induced group, 14.3%
of the hepatitis A viral infection group, 16.7% of the acute Budd–
Chiari group, 18.8% of the hepatitis B viral infection group, as
compared with 100% of acute Wilson’s group, 68.8% of the ful-
minant seronegative hepatitis group and 61.5% of the subacute
necrosis group (Table 2).
When the number of patients transplanted was analysed against
those listed, it was found that 85.9% of the listed seronegative
hepatitis patients were transplanted as opposed to nearly three-
fourth (74.6%) of the listed drug-induced ALF patients (Table 2).
These two aetiologies were compared, both being the bigger
subgroups. The difference was found to be statistically significant
(P = 0.019).
Outcome of transplanted patients
One hundred and eighty-four patients out of the 263, who
received liver graft, are still alive. The overall survival was 70%
with a median survival of 57 months (range: 0–197 months).
After transplantation for ALF, the 1-year, 5-year and 10-
year survival rates were 76.7%, 66% and 47.6%, respectively
(Table 3). When survival was analysed individually for dif-
ferent aetiological subgroups, it was found that acute Wilson’s
disease and hepatitis B viral infection had favourable 1-, 5- and
10-year survival rates and acute Budd–Chiari syndrome had
the lowest survival rates (Table 3). Figure 1 compares the cumu-
lative survival after transplantation in different aetiological
groups. When survival was compared between drug-induced
liver failure and seronegative hepatitis, both being bigger sub-
groups, it was found that seronegative hepatitis had significantly
better 1- and 5-year survival rates (P = 0.002 and P = 0.051
respectively).
Table 2 Number of patients listed and transplanted for acute liver failure (ALF) in different aetiological subgroups
Aetiology ALF (n) Listed – n (%) Transplanted
n (% of listed)
Transplanted
n (% of ALF)
Drug induced 843 118 (14) 88 (74.6) 88 (10.4)
Seronegative hepatitis 186 149 (80.1) 128 (85.9) 128 (68.8)
Hepatitis B 32 10 (31.3) 6 (60) 6 (18.8)
Hepatitis A 14 2 (14.3) 2 (100) 2 (14.3)
Acute Budd–Chiari 18 5 (27.8) 3 (60) 3 (16.7)
Acute Wilson's disease 8 8 (100) 8 (100) 8 (100)
Subacute necrosis 39 25 (64.1) 24 (96) 24 (61.5)
Miscellaneous 97 10 (10.3) 4 (40) 4 (4.1)
Total 1237 327 (26.4) 263 (80.4) 263 (21.3)
Table 3 One-, 5- and 10-year survival of transplanted patients according to aetiological subgroups
Aetiology Transplanted (n) 1-year survival (%) 5-year survival (%) 10-year survival (%)
Drug induced 88 65.9 57.4 42.1
Seronegative hepatitis 128 84.3 72.2 47.5
Hepatitis B 6 100 80 75
Hepatitis A 2 50 50 0
Acute Budd–Chiari 3 0 0 0
Acute Wilson's disease 8 87.5 87.5 85.7
Subacute necrosis 24 75 63.2 53.3
Miscellaneous 4 75 66.7 50
Total 263 76.7 66 47.6
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Post-transplant complications included infection (herpes
viral infection – 44 patients, CMV infection – 28 patients, shingles
– 3 patients and aspergillosis – 5 patients), biliary complications
(bile leak – 10 patients, biliary stricture – 24 patients), malignancy
(Basal cell cancer – 6 patients, lymphoma – 6 patients), graft
complications (primary non-function – 4 patients, chronic
rejection – 13 patients, hepatic artery thrombosis – 13 patients)
and inferior venacaval (IVC) pathology (IVC thrombosis – 1
patient, IVC stenosis – 1 patient).
After transplantation, 79 patients died, of whom 36 died within
30 days of surgery (30-day mortality: 13.7%). Drug-induced liver
failure had the highest 30-day mortality of 21.6%. The 43 patients
who died after 30 days of transplantation, had a median survival
of 10 months (range: 1–189 months). The causes of death in this
group of patients were systemic sepsis (bacterial – 14 patients,
fungal – 7 patients , viral – 3 patients), graft-related complications
(chronic rejection – 5 patients, primary non-function – 1 patient,
hepatic artery thrombosis – 1 patient, lymphoproliferative dis-
order – 2 patients, recurrent disease – 2 patients and metastatic
tumour – 2 patients) and others (suicide – 2 patients and renal
failure, myocardial infarction and cerebrovascular accident – 1
patient each). Out of the two patients who committed suicide, one
died of a paracetamol overdose within 2 months of transplanta-
tion and the other died of a non-medicated method 5 years after
transplantation.
Re-transplantation was performed in 31 patients (11.8%).
The median interval between first transplant and re-graft was
5 months (range: 1 day to 182 months). The indications for
re-transplantation were hepatic artery thrombosis (11 pa-
tients), chronic rejection (10 patients), primary non-function
(4 patients), haemorrhagic necrosis (2 patients), acute rejection
(1 patient), recurrent disease (1 patient) and secondary biliary
cirrhosis (2 patients). Three of the 11 hepatic artery thrombosis
occurred within 2 weeks of primary transplantation and hence
they are likely to be technical failures. Another three patients had
the thrombosis between 2 weeks and 3 months, and the remaining
patients had it after 3 months of transplantation. The aetiology of
hepatic artery thrombosis was not clear in these patients.
Outcome of not transplanted patients
A total of 974 patients did not have transplantation. This includes
the 64 patients who were listed for transplantation but did not
undergo surgery. Among the 64 patients, 49 patients (76.6% and
15% of those listed) died before an organ became available and 15
patients (23.4% and 4.6% of those listed) survived. The aetiology
of ALF in the survived patients was drug-induced liver failure
(8 patients), fulminant seronegative hepatitis (5 patients) and
hepatitis B viral infection (2 patients).
At present, 693 patients are alive. Among the 281 patients
who died, 260 patients (26.7%) died within 30 days of admission.
When 30-day mortality for patients without transplantation was
analysed against different aetiological factors, it was found that
drug-induced liver failure had the best outcome with a 30-day
mortality of 19.6%, followed by subacute necrosis (40%) and
hepatitis A viral infection (41.7%) (Table 4).
Discussion
This study is a large single centre experience of the outcome of
ALF with and without liver transplantation. The study has recon-
firmed that paracetamol overdose (61.2%) is the predominant
cause of ALF in the UK. There was a steady increase in the number
of patients with drug-induced liver injury from 1992 to 1996 (63
patients and 119 patients respectively). Thereafter there was
a decline. This could be attributed partly to a change in central
funding and partly to legislation on pack size. The frequency of
paracetamol-related liver injury in the UK is much higher than
that reported from the US (39%).4 In the US, the majority of
paracetamol overdoses are believed to be accidental, whereas in
the UK the reason for overdose is usually a suicide attempt.4 The
likely reason is that paracetamol is the most widely used non-
prescription analgesic in the UK. Paracetamol when consumed
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Figure 1 Cumulative survival curves comparing different aetiological
groups
Table 4 Thirty-day mortality of non-transplanted patients according
to aetiological subgroups
Aetiology Non-transplanted 30-day
mortality (%)
Drug induced 755 148 (19.6)
Seronegative hepatitis 58 32 (55.2)
Hepatitis B 26 13 (50)
Hepatitis A 12 5 (41.7)
Acute Budd–Chiari 15 8 (53.4)
Acute Wilson's disease 0 –
Subacute necrosis 15 6 (40)
Miscellaneous 93 48 (51.6)
Total 974 260 (26.7)
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within recommended doses is unlikely to cause liver injury but
in an overdose it is a common cause of severe liver injury because
of its dose-related hepatotoxicity and the presence of associated
factors such as alcohol use and starvation.11–13 However, one study
showed that alcohol consumption protected against severe drug-
induced liver injury.4 The same study confirmed that the presence
of diabetes mellitus is an independent risk factor for the develop-
ment of severe drug-induced liver injury.
The present study has shown that ALF as a result of Wilson’s
disease (100%) or seronegative hepatitis (68.8%) had a high
transplantation rate as compared with drug-induced aetiology
(10.4%). This finding was reflected in the study by Ostapowicz
et al.4 This is because of the availability of an antidote (N-acetyl
cysteine) for paracetamol-related liver injury and the ability of
the liver to recover from paracetamol injury. Patients with
paracetamol-induced ALF deteriorate rapidly resulting in mul-
tiple organ failure (MOF). Paradoxically if these patients do not
fulfill the criteria for liver transplantation, the outcome is much
better than for those with other causes.4,7,14 This again proved to be
the case in our study, where 78.3% of patients with drug-induced
ALF survived without transplantation. This could reflect the
fact that the majority of our drug-induced ALF was because of
paracetamol overdose, who have better outcome than the non-
paracetamol drug-induced ALF. However, it was found by Bernal
et al. that once they were listed for transplantation, they were at
a greater risk of deterioration, although post-transplantation
survival was not compromised.8 In our study, this could explain
the fact that significantly fewer drug-induced ALF patients were
transplanted (74.6%), as opposed to listed seronegative hepatitis
patients (85.9%), because drug-induced ALF patients probably
died before an organ became available. After viral-induced ALF,
we found that survival without transplantation was over 50%. The
study by Dhiman et al. analysed outcome of ALF as a result of viral
hepatitis and reported a survival of 32.3% without transplanta-
tion.3 They concluded that the prognostic factors determining
outcome in ALF-complicating viral hepatitis were age >50 years,
presence of raised intracranial pressure at admission, prothrom-
bin time of >100 s at admission and the onset of encephalopathy
7 days after onset of jaundice.3
In the current series, only 21.3% of patients with ALF received
a liver graft. This was comparable to the results reported in earlier
studies.4 This supports the fact that early aggressive supportive
care is the key factor in the management of ALF. Nevertheless, it
might reflect the fact that the majority of the patients with drug-
induced liver failure were not severely poisoned. In our study,
the overall survival after transplantation (70%) was higher than
reported previously (41–67%).4,15–17 After transplantation, the
favourable aetiological factors in terms of outcome were acute
Wilson’s disease, hepatitis B viral infection, seronegative hepatitis
and drug-induced liver failure. The better survival rates could be
attributed to the large number of patients with drug induced ALF,
who were found to have better survival after transplantation based
on previous reports.4 However, in the present study, seronegative
hepatitis patients had significantly better 1-and 5-year survival
after transplantation than the drug-induced ALF patients. This
probably could be explained by the fact that drug-induced ALF
is mostly as a result of suicidal intent and these patients having
ongoing psychological issues. This could have an impact on the
compliance of post-operative immunosuppression and hence on
the complications and survival.
After transplantation, the mortality rate in the current series
is 30% with a median survival of 57 months. In comparison with
previous reports, the majority of the deaths were related to sepsis
and MOF.18–20 Bernal et al. analysed the factors predicting mortal-
ity after transplantation and identified age >45 years, vasopressor
requirement and use of high-risk grafts as independent risk
factors.8 Wigg et al. studied the outcome after transplantation
in 110 patients with seronegative acute liver failure. They found
high donor body mass index, recipient age >50 years and non-
caucasian recipient ethnicity as significant factors predicting early
death.20
In conclusion, drug-induced liver failure still remains the most
common cause of ALF in the UK. Aggressive early supportive
care is associated with good survival in patients not listed for
transplantation. Similarly in listed patients, liver transplantation
when performed has good long-term survival.
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